Overview

Bioequivalence of a Single Subcutaneous Dose of Epoetin Beta in Healthy Japanese and Caucasian Male Subjects

Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
A study to see how a single subcutaneous dose of Epoetin beta (NeoRecormon®) in healthy Japanese compares with a single subcutaneous dose of Epoetin beta (NeoRecormon®) in Caucasian Male subjects. Each subject received a single subcutaneous dose of 50IU/kg of NeoRecormon Multidose solution on Day 1.
Phase:
Phase 1
Details
Lead Sponsor:
InCROM Europe Clinical Research
Treatments:
Epoetin Alfa